Pharmaceutical Business Review
OTC
Anonymous User | Login

Claire Ellen Launches New Analgesic Neuroquell

Published: 09-Mar-2010

Claire Ellen Products, a scientific bio-pharma research company that develops FDA registered, natural, topical, pain relief products using technology, has introduced Neuroquell, a non-prescription analgesic for a variety of acute and chronic neuromusculoskeletal conditions that cause pain.

Neuroquell works by inhibiting or stopping the nerve pain impulse signals as they travel from one nerve cell to another, (called a synapse).

Claire Ellen Products claimed that in clinical and field studies, Neuroquell has been found to relieve pain from painful conditions such as muscle sprains, strains and cramps, joint pain, arthritis, aches, neuralgia, shingles and bruises caused by injury. The roll-on product is used directly on the area of pain.

The company said that Neuroquell is all natural, has no known side-effects, is non-staining, not tested on animals, no prescription is required, and it works within minutes.

Roger Salmonson, president, said: "It causes the nerve endings of the nerve cells to separate from each other and move back towards their own cell body, thus breaking up their ability to communicate. This results in a reduction of pain."

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Capsugel

Providing Innovative Doasge Forms and Solutions to Health Care Customers ...

Cutting Edge Information

Pharmaceutical Business Intelligence Reports ...

Eurand

Pharmaceutical Technologies for Optimal Drug Delivery Solutions ...

Kuecept

Concept Formulation Design ...

Medilingua Translations

The Medical Translation Specialists ...

MHRA

The Medicines and Healthcare Products Regulatory Agency ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

GRACO's New FDA Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New Hydra-Clean

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New 1590 & 3150 Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Customer Testimonial – Astra Zeneca

From the control room to the downstream processing area and with an eye on utilities servi ...

Hygienic Processing

From the control room to the downstream processing area and with an eye on utilities servi ...

Related Companies

No items to display

Suppliers Product News

Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients with Exocrine Pancreatic Insufficiency

Eurand, a global specialty pharmaceutical company, has announced data from a Phase II/III clinical study demonstrating that ZENPEP (pancrelipase) delayed-release capsules significantly improves fat absorption in patients with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis.

Eurand Issued U.S. Patent for ZENPEP (pancrelipase) Delayed-Release Capsules

Eurand, a global specialty pharmaceutical company, has announced the grant of U.S. Patent No. 7,658,918, titled Stable Digestive Enzyme Compositions, by the United States Patent and Trademark Office (USPTO).

Eurand Reports Recent Developments and Fourth Quarter and Full-Year 2009 Financial Results

Eurand, a global specialty pharmaceutical company, today reported revenues for the fourth quarter of 2009 of €30.3 million ($43.4 million), a 28% increase in constant currency from the fourth quarter of 2008. For the year ended 31 December 2009, revenues grew to a record €120.6 million ($172.8 million), up 18% in constant currency from 2008.

Eurand Successfully Completes Registration Procedure for Paracetamol ODT 250mg and 500mg in the European Union

Eurand, a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that the Dutch Medicines Evaluation Board (MEB) informed the Company that the Decentralized Procedure (DCP) for registration of Paracetamol 250 and 500 mg Orodispersible Tablets (ODT) in several EU countries has been successfully completed.

Eurand Announces International Agreements for Once-Daily Extended Release Muscle Relaxant

Eurand, a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that Eurand Inc. has signed three new commercialization, license and supply agreements for its novel extended-release (ER) formulation of the muscle relaxant cyclobenzaprine HCl. Financial terms were not disclosed.

Eurand Announces National Title Sponsorship of New Cystic Fibrosis Foundation Fundraiser

Company donates $300,000 to sponsor ZENPEP(R) CF Cycle for Life Tour series to support cystic fibrosis research.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address